Binodenoson

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[6-[[3-(4-amino-3,5-dicyclopyridin-2-yl)propyl]amino]-9H-purin-9-yl]-3,3-dimethylbutanoic acid | image = Binodenoson.png | width = 200 | CAS_number = 153253-25-5 | ATC_prefix = none | PubChem = 6918494 | ChemSpiderID = 5293730 | UNII = 0F5N573A2Y | KEGG = D03255 | ChEMBL = 2103875 | C=20 | H=26 | N=8 | O=2 | molecular_weight = 410.47 }}

Binodenoson is a pharmacological agent that acts as a selective adenosine A2A receptor agonist. It is primarily investigated for its potential use in myocardial perfusion imaging as a stress agent. This compound is of interest due to its ability to selectively target the A2A receptor, which is predominantly found in the coronary vasculature, leading to vasodilation and increased blood flow to the heart muscle.

Pharmacology

Binodenoson works by mimicking the action of adenosine, a naturally occurring nucleoside that plays a role in energy transfer and signal transduction. By selectively activating the A2A receptors, binodenoson induces coronary vasodilation without significantly affecting other adenosine receptors, such as A1, A2B, and A3, which are associated with undesirable side effects like bronchoconstriction and atrioventricular block.

Clinical Applications

The primary clinical application of binodenoson is in myocardial perfusion imaging (MPI), a non-invasive imaging technique used to assess the blood flow to the heart muscle. During MPI, binodenoson is used as a pharmacological stress agent to simulate the effects of exercise in patients who are unable to undergo physical stress testing. This is particularly useful in diagnosing coronary artery disease (CAD).

Advantages

One of the main advantages of binodenoson over traditional stress agents like adenosine and dipyridamole is its selectivity for the A2A receptor. This selectivity reduces the risk of side effects such as bronchospasm, which is particularly beneficial for patients with asthma or chronic obstructive pulmonary disease (COPD).

Side Effects

While binodenoson is generally well-tolerated, some patients may experience side effects such as headache, dizziness, or flushing. These effects are typically mild and transient. Serious adverse effects are rare but can include hypotension or arrhythmias.

Research and Development

Binodenoson is still under investigation, and its use is not yet widespread. Ongoing research aims to further establish its safety profile and efficacy compared to other pharmacological stress agents.

Also see

• Adenosine receptor
• Myocardial perfusion imaging
• Coronary artery disease
• Pharmacological stress testing

Cardiovascular disease A-Z

Most common cardiac diseases

• Cardiac arrhythmia‎
• Cardiogenetic disorders‎
• Cardiomegaly‎
• Cardiomyopathy‎
• Cardiopulmonary resuscitation‎
• Chronic rheumatic heart diseases‎
• Congenital heart defects‎
• Heart neoplasia‎
• Ischemic heart diseases‎
• Pericardial disorders
• Syndromes affecting the heart‎
• Valvular heart disease‎

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A

• Accelerated idioventricular rhythm
• Acute decompensated heart failure
• Arteriosclerotic heart disease
• Athletic heart syndrome
• Atrial flutter
• Atrioventricular fistula
• Cardiovascular disease in Australia
• Autoimmune heart disease

B

• Brown atrophy of the heart

C

• Ebb Cade
• Cardiac allograft vasculopathy
• Cardiac amyloidosis
• Cardiac asthma
• Cardiac tamponade
• Cardiogenic shock
• Cardiogeriatrics
• Cardiorenal syndrome
• Cardiotoxicity
• Carditis
• Coronary artery aneurysm
• Coronary artery anomaly
• Coronary artery disease
• Spontaneous coronary artery dissection
• Coronary artery ectasia
• Coronary occlusion
• Coronary steal
• Coronary thrombosis
• Coronary vasospasm
• Cœur en sabot
• Coxsackievirus-induced cardiomyopathy

D

• Duke Treadmill Score
• Duroziez's disease

E

• Eisenmenger's syndrome
• Embryocardia
• Endocardial fibroelastosis
• Eosinophilic myocarditis

H

• Heart attack
• Heart failure
• Heart failure with preserved ejection fraction
• Heart to Heart (1949 film)
• High-output heart failure
• Hyperdynamic precordium

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I

• Idiopathic giant-cell myocarditis
• Interventricular dyssynchrony
• Intraventricular dyssynchrony
• Isolated atrial amyloidosis

K

• Keshan disease

L

• Loeffler endocarditis

M

• Mydicar
• Myocardial bridge
• Myocardial disarray
• Myocardial rupture
• Myocardial scarring
• Myocardial stunning
• Myocarditis

N

• Nonbacterial thrombotic endocarditis

O

• OLR1
• Ostial disease

P

• Papillary fibroelastoma
• Pathophysiology of heart failure
• Postpericardiotomy syndrome
• Pulmonary vein stenosis

R

• Right axis deviation
• Roemheld syndrome

S

• Saturated fat and cardiovascular disease
• SCAR-Fc
• Shone's syndrome
• Strain pattern
• Subacute bacterial endocarditis
• Sudden cardiac death of athletes

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

T

• Traumatic cardiac arrest

V

• Ventricular aneurysm
• Vibroacoustic disease
• Viral cardiomyopathy

W

• Waon therapy